Toll-like receptors (TLRs) are evolutionarily conserved receptors of the innate immune system ([@bib32]). The 13 TLRs recognise their unique pathogen-associated molecular patterns like bacterial lipopolysaccharide (TLR4), DNA (TLR9) or flagellin (TLR5) ([@bib32]; [@bib1]). Activation of TLR induces various molecules activating the immune response ([@bib32]; [@bib1]; [@bib13]).

Increased expression of TLRs has been found to associate with the different types of cancer ([@bib29]; [@bib27]; [@bib22]; [@bib30]; [@bib20]), including the development of gastric cancers ([@bib29]; [@bib22]). Toll-like receptor 5 has been shown to regulate gastric cancer cell proliferation ([@bib30]). Interestingly, increased amount of TLR5 has been described in dysplasia of the stomach as well as in uterine cervix, suggesting that TLR5 may have a role in carcinogenesis ([@bib11]). Thus, TLR5 might help identify dysplastic lesions in epithelium ([@bib11]; [@bib22]).

Former studies show that TLR5 is expressed in normal and neoplastic human salivary gland cells ([@bib20]). Activation of TLR5 by flagellin has been shown to induce migration and invasion in adenocarcinoma cells of the human salivary gland ([@bib20]). Also, head and neck squamous cell carcinomas have been shown to express TLR5 ([@bib27]; [@bib19]).

Oral tongue squamous cell carcinomas (OTSCCs) comprise one third of intraoral cancers and their risk factors include, for example, tobacco, alcohol and poor oral hygiene ([@bib17]; [@bib26]; [@bib6]). Even with the recent advances in their treatment, the 5-year survival remains around 50% ([@bib28]). Various molecular markers and factors have been proposed for risk assessment of OTSCC survival or recurrence, but none are currently in clinical use ([@bib2]; [@bib3]; [@bib10]).

Expression of TLR5 in oral squamous cell carcinomas has not been studied before. The aim of this study was to assess whether the TLR5 expression would relate to clinicopathological variables and if it could predict survival or recurrence of tongue squamous cell carcinoma patients.

Materials and methods
=====================

Patients
--------

Paraffin-embedded, archival resection specimens of OTSCC (*n*=119) were obtained from the Department of Pathology, Oulu University Hospital, between the years 1981--2009. The median age of the patients was 66 years (range 27--99). The median follow-up time was 121 months (range 24--298 months) in the surviving patients. The median survival for the study patients was 51 months (range 1--298 months). The patient survival data were acquired from Statistics Finland and other relevant data from the patient records ([Table 1](#tbl1){ref-type="table"}). We were unable to retrieve treatment data from three of the patients and follow-up data from two of the patients. The use of the patient samples and the data enquiry were approved by the Oulu University Hospital Ethics Committee and by the National Authority for Medicolegal Affairs (VALVIRA).

Immunohistochemistry
--------------------

Immunohistochemistry was performed on the tissue block sections, which were first selected on the basis of haematoxylin and eosin stainings, to be representative for the tumour mass in the resected specimen. The TLR5 immunostainings were performed with a commercial monoclonal mouse antibody (IMG-664A, IgG2a, Clone 19D759.2, Imgenex, San Diego, CA, USA), with dilution of 1:150. For immunohistochemical detection of the antibody reaction, we used Dako Envision kit (Dako, Copenhagen, Denmark) with a high temperature antigen retrieval in Tris-EDTA buffer for 15 min. Diaminiobenzidine (Dako basic DAB-kit) was used as a chromogen. All the stainings were done with Dako Autostainer (Dako). Validation of our immunohistochemical analysis was performed through two series of negative controls (by omitting the primary antibody and by replacing primary antibody with mouse primary antibody isotype control).

Assessment of TLR5 expression
-----------------------------

Immunoreaction of TLR5 was analysed by two independent researchers (JHK and AM) blinded from the clinical data. The staining intensities and the percentage of positive cells were separately assessed in the primary tumour tissue (*n*=119) and adjacent normal squamous epithelium (*n*=101). As the TLR5 staining was not uniform in different parts of the epithelium or cancerous tissue ([Figures 1](#fig1){ref-type="fig"} and 3), we chose to use a modified histoscore method, as described earlier ([@bib9]), to combine the TLR5 intensity and percentage of TLR5 expressing cells. More specifically, the staining intensity was assessed with a four-point scale from negative (0) to weak (1), moderate (2) and strong intensity (3). The extent of the staining was expressed as percentage of positive cells (0--100%) by 10% intervals. The mean values of the two independent estimates were used if the estimated staining intensity scores did not differ more than by one step, or if the difference of proportion of positive cells was \<30%. In cases with more extensive differences between the assessors a consensus was reached after a re-evaluation. The TLR5 histoscore was counted by multiplying the mean of intensity level by the mean percentage of positive cells, resulting in a value between 0 and 300. Data were divided into groups by histoscore levels. Accordingly, the cancer specimens were dichotomised by TLR5 expression score based on the median to the groups of 'weak expression\' (scores 0--135) and 'strong expression\' (scores 136--300).

Statistical analysis
--------------------

For statistical analyses, we used SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and Prism 6 for Mac OS X (GraphPad Software Inc., La Jolla, CA, USA). Chi-square test was used to calculate statistically significant differences between prognostic and clinicopathologic variables. To compare the TLR5 expression in normal and cancerous tissue, independent samples *t*-test and paired samples *t*-test were used. The correlation of staining intensity and percentage was done with Spearman\'s rho test. Life tables were calculated according to the Kaplan--Meier method, and the survival curves were compared with the log-rank test. Uni- and multivariate survival analysis was done with the Cox proportional hazards model using the following covariates: TLR5 expression (weak and strong), gender, age at the time of diagnosis (\<55, 55--70 and \>70 years), tumour stages (1--2 and 3--4), tumour histologic grades (1, 2 and 3) and adjuvant therapy (no adjuvant therapy, radiotherapy or chemo- and radiotherapy). Multivariate analysis was done using backward stepwise selection of variables, and a *P*-value of 0.05 was adopted as the limit for inclusion of a covariate. The backward stepwise algorithm was used to pick the best combination of prognostic factors to explain the mortality or recurrences in the study population. The hazard ratios (HRs) and 95% confidence intervals (CIs) are provided for each covariate.

Results
=======

TLR5 is expressed in normal tongue epithelium
---------------------------------------------

Toll-like receptor 5 was expressed in 84 (83.2%) of the 101 normal adjacent squamous epithelia surrounding the tongue cancer tissue. The staining was localised in the cytoplasm and when present, mainly found in the basal layer of the epithelium ([Figures 1A](#fig1){ref-type="fig"} and 3A--C). Thus, the staining intensity varied from 0 to 3 and the percentage was mainly between 0 and 30 with a few higher percentages.

TLR5 expression is increased in OTSCC and associates with disease recurrence
----------------------------------------------------------------------------

Toll-like receptor 5 was expressed in 118 (99.2%) of the 119 tumours evaluated, with predominantly cytoplasmic location of the immunoreaction ([Figure 1B and C](#fig1){ref-type="fig"}). The expression of TLR5 in cancerous tissue was increased in both stage 1--2 and stage 3--4 cancers, when compared with adjacent normal epithelium (*P*\<0.001, [Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Median histoscores in normal mucosa, stage 1--2 cancer and stage 3--4 cancer were 15, 135 and 130, accordingly. The median histoscore for all cancers was 135. The variance of staining percentage was higher in cancer tissue than in normal mucosa the percentage ranging from 0 to 100, with only one negative sample. The intensities ranged between 0 and 3 and there was a correlation between the staining intensity and percentage (*ρ*=0.742, *P*\<0.001).

We found significant association between weak TLR5 expression and younger age (*P*\<0.01), male gender (*P*\<0.05), as well as strong TLR5 expression and disease recurrence (*P*\<0.001). No significant association was detected between TLR5 expression and tumour grade, stage, lymph-node status or treatment. The associations are summarised in [Table 2](#tbl2){ref-type="table"}.

Survival and recurrence, univariate analysis
--------------------------------------------

We analysed the effect of TLR5 on disease recurrence as well as cancer mortality. Strong TLR5 expression was associated with reduced disease-free survival (*P*\<0.001, [Figure 4B](#fig4){ref-type="fig"}). Strong TLR5 expression was also associated with increase in cancer-specific mortality (*P*\<0.01, [Figure 4A](#fig4){ref-type="fig"}).

Strong TLR5 expression is an independent predictor of survival in multivariate analysis
---------------------------------------------------------------------------------------

Multivariate analysis ([Table 3](#tbl3){ref-type="table"}), *n*=117, 39 events, identified strong TLR5 expression as an independent prognostic factor (HR 3.587, 95% CI (1.632--7.882)) for cancer-specific deaths, along with poor grade of differentiation and high disease stage (III--IV). Strong TLR5 expression was also identified as an independent predictor of recurrences (HR 4.455, 95% CI (2.168--9.158)).

Discussion
==========

Toll-like receptor 5 recognises bacterial flagellin and it has been shown to affect cancer progression *in vitro* ([@bib1]; [@bib20]). In this study, we show for the first time that TLR5 expression is increased in OTSCC when compared with surrounding normal lingual epithelium. We also demonstrate that TLR5 expression is an independent predictor of OTSCC mortality and disease recurrence.

Inflammation caused by microbial infections is known as a carcinogenetic factor for many cancers, for example, *Helicobacter pylori* infection and gastric cancer ([@bib16]). Human papilloma virus (HPV) infection is a defined risk factor for oral squamous cell carcinoma, but its prevalence in cancers of the mobile tongue is much lower than in cancers of the base of the tongue ([@bib5]; [@bib6]; [@bib7]). Presence of HPV in oropharyngeal cancers seem to associate with better prognosis ([@bib21]). Thus, other factors explaining the mortality related to OTSCC are needed.

In the oral cavity, the role of microbiota in carcinogenesis is currently unknown, even though poor oral hygiene is a risk factor for OTSCC ([@bib26]). Interestingly, it has been shown that *Streptococcus mitis*, *Prevotella melaninogenica* and *Capnocytophaga gingivalis* species are prevalent in oral cancer patients with high specificity and sensitivity ([@bib14]). Their effect on oral carcinogenesis, however, remains to be revealed. Acetaldehyde production by bacteria might partly explain the link between bacteria and oral cancer as well as the effect of alcohol consumption on oral cancer ([@bib16]).

Earlier reports by us and others have demonstrated a role for various TLRs in cancer progression, as well as immune responses against cancer ([@bib15]; [@bib25]; [@bib8]; [@bib33]; [@bib18]; [@bib31]). Polymorphisms of TLR have also been found to affect cancer development ([@bib12]; [@bib34]). Expression of TLR5 has been shown to increase during gastric and colorectal carcinogenesis, as well as in precancerous lesions of uterine cervix ([@bib11]; [@bib23], [@bib24]). Toll-like receptor 5 has also been proposed as a biomarker for gastric and cervical dysplasias, because its expression increases through stages of cancer development ([@bib11]; [@bib22]). In various gastric cancer cell lines, stimulation with flagellin increased proliferation and induced IL-8 via TLR5 ([@bib30]). In breast cancer, for example, TLR5 expression was increased in ductal adenocarcinoma cells ([@bib4]). In contrary to gastric cancer, activation by flagellin resulted in tumour suppressive effects in some of the breast cancer cell lines, whereas other cell lines were unresponsive to flagellin ([@bib4]). Antitumor effect by flagellin has also been demonstrated in a pharyngeal carcinoma cell line ([@bib27]). In salivary gland cancer cells, TLR5 activation induced invasion and proliferation ([@bib20]). According to the studies by [@bib19] TLR5 activation, despite the increase in production of tumour-promoting IL-6 and IL-8, did not influence cell proliferation, invasion, migration or angiogenesis in moderately differentiated YD-10B OTSCC cells (). However, the effect of TLR5 stimulation on OTSCC progression may not be generalised from *in vitro* experiments with only single cell line.

The downstream effects and functionality of TLR5 seem to be dependent on cancer type, location and cell line. One explanation would be the mucosal bacteria, which are abundant in the gastrointestinal tract, but less prevalent for example in the mammary glands. During carcinogenetic changes, the expression pattern of TLR5 changes from basolateral to diffuse or increases on the luminal surface, as shown earlier, likely facilitating the recognition of bacterial particles ([@bib11]; [@bib23]).

Our results suggest a link between TLR5 and oral squamous cell cancer progression. The bacterial flora changes during oral carcinogenesis and thus the flagella of oral bacteria could be recognised by TLR5, which in turn might affect the release of tumour promoting cytokines in cancer cells or induce cancer cell invasion ([@bib19], [@bib20]). Thus, the composition of bacterial flora might also have a TLR5-dependent effect on cancer development. Oral tongue squamous cell carcinoma has low 5-year survival ([@bib28]), but there are no clinically practical markers for risk assessment of OTSCC survival or recurrence ([@bib2]; [@bib3]; [@bib10]). Our study provides evidence for a relationship of TLR5 expression levels and prognosis in OTSCC. Multivariate analysis confirmed an independent association between high expression and recurrence of the tumour and poor survival. Similar prognostic value for TLR5 expression in cancer has not been demonstrated earlier.

There are some shortcomings in our study. The retrospective design may result in unknown biases in data. The long follow-up gives more reliable results, but the treatments have undergone slight changes during the 30 years, which cannot be controlled. Other things include the use of semiquantitative immunohistological assessment and the lack of functional TLR5 experiments.

In summary, we demonstrate a role for bacterial flagellin recognising TLR5 in OTSCC. Toll-like receptor 5 could be considered as a useful marker for predicting recurrence or survival of tongue carcinoma patients. It might be a useful tool to help recognise the OTSCC patients needing more intensive treatment and follow-up or even a potential new therapeutic target. The results should be evaluated using more extensive, prospective patient materials and *in vitro* functional studies to ensure these findings.
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###### Baseline characteristics of the patients

  **Patient clinical data**   ***N***   **%**
  --------------------------- --------- -------
  Total                       119       100.0
  **Age at diagnosis**                  
  \<55 years                  37        31.1
  55--70 years                33        27.7
  \>70 years                  49        41.2
  **Sex**                               
  Male                        58        48.7
  Female                      61        51.3
  **Tumour grade**                      
  1                           41        34.5
  2                           63        52.9
  3                           15        12.6
  **Tumour stage**                      
  1--2                        61        51.3
  3--4                        58        48.7
  **Neck lymph nodes**                  
  Negative                    78        65.5
  Positive                    41        34.5
  **Recurrence**                        
  No                          78        65.5
  Yes                         41        34.5
  **Adjuvant therapy**                  
  No                          68        57.1
  Radiotherapy                38        31.9
  Radio- and chemotherapy     10        8.4
  Missing                     3         2.5

###### Tumour TLR5 status and clinical correlations

                           **TLR5 expression**               
  ------------------------ --------------------- ----------- ---------
  **Age at diagnosis**                                       
  \<55 years               27 (73.0)             10 (27.0)    
  55--70 years             12 (36.4)             21 (63.6)    
  \>70 years               23 (46.9)             26 (53.1)   \<0.01
  **Sex**                                                    
  Male                     36 (62.1)             22 (37.9)    
  Female                   26 (42.6)             35 (57.4)   \<0.05
  **Tumour grade**                                           
  1                        18 (43.9)             23 (56.1)    
  2                        35 (55.6)             28 (44.4)    
  3                        9 (60.0)              6 (40.0)    NS
  **Tumour stage**                                           
  1--2                     31 (50.8)             30 (49.2)    
  3--4                     31 (53.4)             27 (46.6)   NS
  **Neck lymph nodes**                                       
  Negative                 43 (55.1)             35 (44.9)    
  Positive                 19 (46.3)             22 (53.7)   NS
  **Recurrence**                                             
  No                       52 (66.7)             26 (33.3)    
  Yes                      10 (24.4)             31 (75.6)   \<0.001
  **Adjuvant treatment**                                     
  No                       36 (52.9)             32 (47.1)    
  RT                       18 (47.4)             20 (52.6)    
  RT and chemotherapy      5 (50.0)              5 (50.0)    NS

Abbreviations: NS=non-significant; RT=radiotherapy; TLR5=Toll-like receptor 5.

###### Multivariate analysis

                                                  **HR**    **95% CI**
  ---------------------------------------------- -------- --------------
  **Multivariate analysis: cancer mortality**             
  *Tumour stage*                                                 
   1--2                                           1.000          
   3--4                                           4.288    1.999--9.200
  *Tumour grade*                                                 
   1                                              1.000          
   2                                              0.905    0.427--1.919
   3                                              3.221    1.257--8.255
  *TLR5 expression*                                              
   Weak                                           1.000          
   Strong                                         3.587    1.632--7.882
  **Multivariate analysis: cancer recurrence**            
  *TLR5 expression*                                              
   Weak                                           1.000          
   Strong                                         4.455    2.168--9.158

Abbreviations: CI=confidence interval; HR=hazard ratio; TLR5=Toll-like receptor 5.
